New Imaging Score May Predict Chemo Benefit in Early OPSCC New Imaging Score May Predict Chemo Benefit in Early OPSCC
If validated, this scoring system could help identify patients with oropharyngeal squamous cell carcinoma who can skip chemo. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 27, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Neoadjuvant Immunochemotherapy Promising in Oral SCC Neoadjuvant Immunochemotherapy Promising in Oral SCC
A small trial reported a 60% response rate to neoadjuvant immunochemotherapy in oral squamous cell carcinoma. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 29, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Post-op Chemo Has Limited Benefit in Some Esophageal Cancers Post-op Chemo Has Limited Benefit in Some Esophageal Cancers
Patients with stage IIA and IIB esophageal squamous cell carcinoma with lymphovascular invasion but negative lymph nodes do not benefit. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 16, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Solid organ transplant patients are at higher risk of skin cancer and require coordinated care, Mayo Clinic researchers find
More than half of all patients who receive solid organ transplants will have an incidence of skin cancer at some point — most often a nonmelanoma cancer, such as basal cell carcinoma or squamous cell carcinoma. This increased risk can be several hundred times higher than in the general population. The increased risk is related to long-term immunosuppressive therapy required for transplanted organ survival, which a ffects the immune system's ability to monitor cells for abnormalities.… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 5, 2022 Category: Databases & Libraries Source Type: news

Nivolumab Promising for Treatment of Advanced Cutaneous SCC
Robust antitumor activity and good tolerability observed in phase 2 study of nivolumab for first - line treatment of advanced cutaneous squamous cell carcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 24, 2022 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Journal, Source Type: news

Nivolumab Promising for Treatment of Advanced Cutaneous SCC
MONDAY, Oct. 24, 2022 -- For advanced cutaneous squamous cell carcinoma (aCSCC), first-line treatment with nivolumab shows robust antitumor activity and good tolerability, according to a study published online Oct. 24 in Cancer. Rodrigo R. Munhoz,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 24, 2022 Category: Pharmaceuticals Source Type: news

Rare Mesothelioma Cancer Discovered in Quarter Horse
No one is immune to the effects of toxic asbestos fibers, the primary cause of mesothelioma cancer. Not even horses. Although mesothelioma is a rare cancer in humans, it is even more rare in animals, particularly horses that spend most of their time grazing outdoors. But it still happens. Both pleural mesothelioma and peritoneal mesothelioma cancer were identified during the autopsy of a 22-year-old gelding quarter horse that had spent much of its working life in equestrian tourism activities. Animals, an international peer-reviewed journal devoted to veterinary sciences, detailed the rare mesothelioma case report...
Source: Asbestos and Mesothelioma News - October 4, 2022 Category: Environmental Health Authors: Fran Mannino Source Type: news

Neoadjuvant Pembrolizumab Not Tied to More AEs in Oral Cavity SCC
No increased perioperative morbidity seen among patients with local regionally advanced oral cavity squamous cell carcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 15, 2022 Category: Cancer & Oncology Tags: Oncology, ENT, Pharmacy, Surgery, Journal, Source Type: news

Neoadjuvant Pembrolizumab Not Tied to More AEs in Oral Cavity SCC
THURSDAY, Sept. 15, 2022 -- Among patients with local regionally advanced oral cavity squamous cell carcinoma, rates of postoperative adverse events appear to be similar for those receiving neoadjuvant pembrolizumab or standard-of-care treatment,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2022 Category: Pharmaceuticals Source Type: news

Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinoma
(MedPage Today) -- PARIS -- Neoadjuvant therapy with cemiplimab (Libtayo) achieved deep pathologic responses in patients with resectable cutaneous squamous cell carcinoma (cSCC), according to research presented here. Among 79 patients treated... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - September 13, 2022 Category: Dermatology Source Type: news

Cemiplimab Studied as Neoadjuvant Therapy for Cutaneous SCC
MONDAY, Sept. 12, 2022 -- Fifty-one percent of patients receiving neoadjuvant therapy with cemiplimab for resectable stage II, III, or IV (M0) cutaneous squamous cell carcinoma had a pathological complete response, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 12, 2022 Category: Pharmaceuticals Source Type: news

Add-On Pembrolizumab Misses in Locally Advanced Head and Neck Cancer
(MedPage Today) -- PARIS -- Combining a PD-1 inhibitor with standard chemoradiotherapy (CRT) failed to significantly improve survival outcomes in unresectable locally advanced head and neck squamous cell carcinoma, results of the phase III KEYNOTE... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 11, 2022 Category: Hematology Source Type: news

Additional types of cancer reported in people with breast implants, FDA says
The US Food and Drug Administration is alerting the public about certain cancers -- including squamous cell carcinoma and various lymphomas -- that have been reported in the scar tissue that forms around breast implants. (Source: CNN.com - Health)
Source: CNN.com - Health - September 10, 2022 Category: Consumer Health News Source Type: news

FDA Warns of Rare Cases of Certain Cancers Linked to Breast Implants
FRIDAY, Sept. 9, 2022 -- The U.S. Food and Drug Administration on Thursday warned doctors and their patients about rare cases of squamous cell carcinoma (SCC) and various lymphomas developing in the scar tissue that forms around breast implants.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 9, 2022 Category: Pharmaceuticals Source Type: news